Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-03-31
DOI
10.1016/j.annonc.2021.03.204
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade
- (2020) Allison Betof Warner et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term immune-related adverse events under PD-1 inhibitors: a multicenter prospective cohort study (MELBASE).
- (2020) Charlee Nardin et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research
- (2020) Douglas B Johnson et al. LANCET ONCOLOGY
- Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma
- (2019) Y J L Jansen et al. ANNALS OF ONCOLOGY
- Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
- (2019) O Hamid et al. ANNALS OF ONCOLOGY
- Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
- (2019) Elisa A Rozeman et al. LANCET ONCOLOGY
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
- (2019) Caroline Robert et al. LANCET ONCOLOGY
- A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis
- (2019) Douglas B. Johnson et al. NATURE MEDICINE
- Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance
- (2019) Marcus A. Couey et al. Journal for ImmunoTherapy of Cancer
- Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation
- (2019) Tawnie J Braaten et al. ANNALS OF THE RHEUMATIC DISEASES
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
- (2018) Caroline Robert et al. JOURNAL OF CLINICAL ONCOLOGY
- FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma
- (2018) A C Tan et al. ANNALS OF ONCOLOGY
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
- (2017) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started